Glaucoma is classically defined by optic neuropathy, visual field loss, and often – but not always – elevated intraocular pressure (IOP). Yet up to half of patients develop glaucomatous damage despite having “normal” IOP, highlighting the need to look beyond pressure alone. A new study proposes an unexpected systemic contributor: the mechanical fragility of red blood cells.
In the large case-control analysis, researchers from the University of Electronic Science and Technology of China reported that erythrocyte osmotic fragility (EOF) – a measure of how easily red blood cells rupture under osmotic stress – is significantly increased in patients with glaucoma and may serve as a novel blood-based biomarker for disease risk and severity.
The study included 175 patients with glaucoma and 175 age- and sex-matched healthy controls, all rigorously phenotyped by glaucoma specialists. Importantly, patients with conditions known to affect red blood cells, such as hemolytic anemia or severe iron deficiency anemia, were excluded to minimize confounding. Peripheral blood samples were analyzed using a standard automated hematology analyzer, complemented by a classic osmotic fragility assay in graded sodium chloride solutions.
The results revealed that red blood cells from patients with glaucoma showed significantly higher erythrocyte osmotic fragility than those from controls, meaning they ruptured at higher saline concentrations. This finding was consistent across glaucoma subtypes, including primary open-angle and primary angle-closure glaucoma, and EOF values increased progressively with disease severity, “suggesting a significant positive correlation between EOF and the severity of glaucoma.” Giemsa staining confirmed a higher proportion of abnormally shaped erythrocytes in glaucoma patients, in line with greater membrane instability.
The authors go on to propose several plausible mechanisms linking erythrocyte fragility to glaucomatous damage. Increased EOF is a known consequence of chronic oxidative stress and systemic inflammation, both of which are increasingly implicated in glaucoma pathophysiology. Fragile red blood cells are less deformable and more prone to rupture in the microcirculation, impairing oxygen delivery. Retinal ganglion cells have exceptionally high metabolic demands, and even subtle reductions in oxygen supply may increase their vulnerability to injury.
The study also raises an intriguing secondary hypothesis: ruptured erythrocytes may generate so-called “ghost cells” – cell membranes which can appear as shadowy, faint outlines when viewed through a microscope – that obstruct aqueous outflow pathways, potentially contributing to IOP elevation in some patients. While speculative, this mechanism has historical precedent and reinforces the idea that systemic and ocular factors may intersect in glaucoma in unexpected ways.
To test the clinical utility of EOF, the study authors applied least absolute shrinkage and selection operator (LASSO) regression model to identify blood-based predictors of glaucoma. An initial model using routine blood markers alone performed poorly. However, when EOF was incorporated, predictive accuracy rose dramatically. The final model – combining EOF with selected haematological parameters – achieved 88.7% accuracy, 92.6% sensitivity, and 84.6% specificity, indicating excellent discrimination between glaucoma and control subjects.
Perhaps most intriguing was a small family study included in the analysis. In one asymptomatic young family member with elevated EOF but normal baseline imaging, glaucomatous changes – such as thinning of the retinal nerve fiber layer and an increased cup-to-disc ratio – became detectable in an OCT follow-up one year later. While anecdotal, this observation hints that EOF abnormalities may precede structural damage detectable by current ophthalmic imaging.
That said, the study does not suggest that EOF testing is ready for routine clinical use. Larger, longitudinal studies are now needed, and standardization across laboratories will be essential. Nevertheless, the findings are provocative. EOF testing is inexpensive, technically simple, and already familiar to clinical laboratories – qualities that make it attractive as a potential screening or risk-stratification tool. If validated, blood-based biomarkers such as EOF could one day complement imaging and perimetry, helping identify patients at risk earlier – and reminding us that sometimes, the clues to optic nerve disease lie far beyond the eye.
